Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer

被引：16

作者：

Byrne B.J. ^{[1
]}

Garst J. ^{[1
]}

机构：

[1] Duke University Medical Center, Durham, NC 27710

来源：

Current Oncology Reports | 2005年 / 7卷 / 4期

关键词：

Lung Cancer; Epidermal Growth Factor Receptor; Docetaxel; Brain Metastasis; Clin Oncol;

D O I：

10.1007/s11912-005-0045-6

中图分类号：

学科分类号：

摘要：

The epidermal growth factor receptor (EGFR) is a promising target in the treatment of advanced stage non-small-cell lung cancer (NSCLC). Currently erlotinib and gefitinib are approved by the US Food and Drug Administration, whereas cetuximab is being studied for use in NSCLC. Erlotinib has shown a survival advantage in patients with advanced NSCLC. Further studies have identified female sex, non-smokers, Asian race, good performance status, and adenocarcinoma histology as predictors of patient response to these agents. A genetic mutation in EGFR has also been correlated with an increase in response. Copyright © 2005 by Current Science Inc.

引用

页码：241 / 247

页数：6

共 42 条

[1]

Jemel A., Murray T., Ward E., Et al., Cancer statistics, 2005, CA Cancer J. Clin., 55, pp. 10-30, (2005)

[2]

Byrne B., Crawford J., Gay G., Et al., Trends in chemotherapy use and survival for patients with metastatic non-small cell lung cancer, Proc. ASCO, 13, (2004)

[3]

Cella D., Bonomi A., Lloyd S., Et al., Reliability and validity of the Functional Assessment of Cancer Therapy - Lung (FACT-L) quality of life instrument, Lung Cancer, 12, pp. 199-220, (1995)

[4]

Schiller J., Harrington D., Belani C., Et al., Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer, N. Engl. J. Med., 346, pp. 92-98, (2002)

[5]

Shepherd F., Dancey J., Ramlau R., Et al., Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy, J. Clin. Oncol., 18, pp. 2095-2103, (2000)

[6]

Massarelli F., Andre F., Liu D., Et al., A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer, Lung Cancer, 39, pp. 55-61, (2002)

[7]

Arteaga C.L., ErbB-targeted therapeutic approaches in human cancer, Exp. Cell Res., 284, pp. 122-130, (2003)

[8]

El-Rayes B., LoRusso P., Targeting the epidermal growth factor receptor, Br. J. Cancer, 91, pp. 418-424, (2004)

[9]

Perez-Soler R., HER1/EGFR targeting: Refining the strategy, Oncologist, 9, pp. 58-67, (2004)

[10]

Kris M., Natale R., Herbst R., Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer, JAMA, 16, pp. 2149-2158, (2003)

← 1 2 3 4 5 →